Loading
Neuregen Therapeutics is testing an injection for high-grade brain tumours that combines a cancer-killing virus, an immune booster and a technique meant to turn leftover tumour cells into cells that no longer divide.
Neuregen Therapeutics Co., Ltd. (纽伦捷生物), whose Wuhan entity was founded in December 2021 according to the company and whose website gives a Shanghai address, develops therapies based on in vivo cell reprogramming (in situ transdifferentiation), with a pipeline focused on nervous system tumours and blinding eye disease. NRG-103 injection combines a recombinant oncolytic virus, an immune-enhancing cytokine and in situ transdifferentiation of residual tumour cells; the company reports FDA IND clearance and orphan drug designation, and implied IND approval from China's CDE in January 2026. A phase 1 trial is enrolling patients with recurrent or progressive high-grade glioma (NCT07710690). The company announced a Series A in May 2026, led by a Wuhan Optics Valley fund. Its first registered cancer trial, NCT07710690, was posted on ClinicalTrials.gov in July 2026.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Wuhan Optics Valley Science and Innovation Industry Investment Fund; amount not stated. The company says 2025 financing totalled nearly RMB 100 million | 2026 | undisclosed | nrg-therapeutics.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Cytokines & engineered cytokines, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Oncolytic viruses, Glioma & glioblastoma.
Shares Cytokines & engineered cytokines, Glioma & glioblastoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/